
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$70.91
+US$2.70 · +3.96%
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
前收盘价
US$70.91
+US$2.70 · +3.96%
盘中时间采用ET。市场数据可能有所延迟。
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
日内区间
当前US$70.91
52周区间
当前US$70.91
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
53
合理估值
情绪
56
多空交织
风险
49
风险偏高
动量
45
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
日内区间
当前US$70.91
52周区间
当前US$70.91
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 20.4亿 USD | 18.3亿 USD | 16.17亿 USD | 14.3亿 USD | 13.15亿 USD |
| 销货成本 | 19.49亿 USD | 15.81亿 USD | 13.95亿 USD | 12.64亿 USD | 11.23亿 USD |
| 毛利 | 9080.4万 USD | 2.49亿 USD | 2.21亿 USD | 1.66亿 USD | 1.92亿 USD |
| 营业费用 | — | 1.44亿 USD | 1.23亿 USD | 1.19亿 USD | 1.09亿 USD |
| 利息支出 | 6991.3万 USD | 7984.9万 USD | 6448.3万 USD | 5084.1万 USD | 4883万 USD |
| 折旧和摊销 | 1.52亿 USD | 1.38亿 USD | 1.89亿 USD | 1.85亿 USD | 1.71亿 USD |
| 营业利润 | 9080.4万 USD | 1.05亿 USD | 9869.7万 USD | 4636.3万 USD | 8255.4万 USD |
| 净利润 | −1865.2万 USD | 279.3万 USD | 304.4万 USD | 1065万 USD | 2472.7万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$65.00
下跌空间 8.33%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2006年11月28日 | 1:2 | — | — |
已生效 2006年11月28日
1:2
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR2.4亿0.23%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI1.71亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1.28亿0.16%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB1.23亿0.07%1853亿 USD0.03%US$289.48+0.64%
Defiance Quantum ETFQTUM8036.14万1.40%57.41亿 USD0.40%US$152.06+0.78%
Vanguard Morningstar Small-Cap Growth ETFVBK7090.38万0.16%447亿 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF6237.42万0.06%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO4508.8万0.33%139.17亿 USD0.24%US$356.78+0.94%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Defiance Quantum ETFQTUM
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。